Skip to main content

To trade in the US, go to polymarket.us

icon for Merck & Moderna merger/acquisition announced in 2026?
Finance·M&A

Merck & Moderna merger/acquisition announced in 2026?

icon for Merck & Moderna merger/acquisition announced in 2026?
Finance·M&A

Merck & Moderna merger/acquisition announced in 2026?

1% chance
Polymarket
NEW
1% chance
Polymarket
NEW
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries. An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs. A bid or offer announcement without the indication of a settled agreement will not qualify. Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count. The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 data for the companies’ partnered mRNA cancer vaccine intismeran autogene, which drove sharp share-price gains in August 2026, has reinforced their decade-long collaboration without prompting consolidation talks. Merck continues to pursue bolt-on acquisitions in life sciences and oncology, such as its Bio-Techne and Terns deals, while Moderna focuses on pipeline prioritization, licensing select assets, and manufacturing scale-up for individualized therapies. Market-implied odds near 99% against a 2026 announcement reflect this stable partnership structure, differing strategic priorities, and absence of regulatory or activist pressure for a merger. Tail risks remain limited to an unforeseen macroeconomic shock or sudden board-level strategic pivot, both viewed as remote given current capital allocation and competitive positioning.

This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.

An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.

A bid or offer announcement without the indication of a settled agreement will not qualify.

Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.

The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries. An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs. A bid or offer announcement without the indication of a settled agreement will not qualify. Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count. The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425
End Date
Jan 1, 2027
Market Opened
Aug 19, 2026, 3:58 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries. An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs. A bid or offer announcement without the indication of a settled agreement will not qualify. Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count. The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 data for the companies’ partnered mRNA cancer vaccine intismeran autogene, which drove sharp share-price gains in August 2026, has reinforced their decade-long collaboration without prompting consolidation talks. Merck continues to pursue bolt-on acquisitions in life sciences and oncology, such as its Bio-Techne and Terns deals, while Moderna focuses on pipeline prioritization, licensing select assets, and manufacturing scale-up for individualized therapies. Market-implied odds near 99% against a 2026 announcement reflect this stable partnership structure, differing strategic priorities, and absence of regulatory or activist pressure for a merger. Tail risks remain limited to an unforeseen macroeconomic shock or sudden board-level strategic pivot, both viewed as remote given current capital allocation and competitive positioning.

This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.

An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.

A bid or offer announcement without the indication of a settled agreement will not qualify.

Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.

The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries. An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs. A bid or offer announcement without the indication of a settled agreement will not qualify. Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count. The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$425
End Date
Jan 1, 2027
Market Opened
Aug 19, 2026, 3:58 PM ET

Resolver

0x65070BE91...

Related

icon for Will MGM Resorts be acquired before 2027?

Will MGM Resorts be acquired before 2027?

38%
icon for Will Coingecko be acquired in 2026?

Will Coingecko be acquired in 2026?

14%
icon for Will fomo.family be acquired in 2026?

Will fomo.family be acquired in 2026?

14%

Beware of external links.

Frequently Asked Questions

"Merck & Moderna merger/acquisition announced in 2026?" is a prediction market on Polymarket where traders buy and sell "Yes" or "No" shares based on whether they believe this event will happen. The current crowd-sourced probability is 1% for "Yes." For example, if "Yes" is priced at 1¢, the market collectively assigns a 1% chance that this event will occur. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

"Merck & Moderna merger/acquisition announced in 2026?" is a newly created market on Polymarket, launched on Aug 19, 2026. As an early market, this is your opportunity to be among the first traders to set the odds and establish the market's initial price signals. You can also bookmark this page to track volume and trading activity as the market gains traction over time.

To trade on "Merck & Moderna merger/acquisition announced in 2026?," simply choose whether you believe the answer is "Yes" or "No." Each side has a current price that reflects the market's implied probability. Enter your amount and click "Trade." If you buy "Yes" shares and the outcome resolves as "Yes," each share pays out $1. If it resolves as "No," your "Yes" shares pay $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current probability for "Merck & Moderna merger/acquisition announced in 2026?" is 1% for "Yes." This means the Polymarket crowd currently believes there is a 1% chance that this event will occur. These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen.

The resolution rules for "Merck & Moderna merger/acquisition announced in 2026?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.